808 related articles for article (PubMed ID: 26938871)
21. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Wong KM; Noonan S; O'Bryant C; Jimeno A
Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
[TBL] [Abstract][Full Text] [Related]
22. Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).
Iwama E; Goto Y; Murakami H; Harada T; Tsumura S; Sakashita H; Mori Y; Nakagaki N; Fujita Y; Seike M; Bessho A; Ono M; Okazaki A; Akamatsu H; Morinaga R; Ushijima S; Shimose T; Tokunaga S; Hamada A; Yamamoto N; Nakanishi Y; Sugio K; Okamoto I
J Thorac Oncol; 2017 Jul; 12(7):1161-1166. PubMed ID: 28238961
[TBL] [Abstract][Full Text] [Related]
23. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
24. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
Srinivasamaharaj S; Salame BK; Rios-Perez J; Kloecker G; Perez CA
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1227-1233. PubMed ID: 27744726
[TBL] [Abstract][Full Text] [Related]
25. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
26. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
27. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
28. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
30. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
Arbour KC; Riely GJ
Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
[TBL] [Abstract][Full Text] [Related]
33. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
34. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
35. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
36. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
37. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
38. Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC.
Zhu Q; Hu H; Weng DS; Zhang XF; Chen CL; Zhou ZQ; Tang Y; Xia JC
BMC Cancer; 2017 Jun; 17(1):412. PubMed ID: 28606126
[TBL] [Abstract][Full Text] [Related]
39. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]